Raptor Pharma (RPTP) Acquires IP Related to Parkinson's Disease from Université Laval

June 20, 2012 6:35 AM EDT Send to a Friend
Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that the Company has acquired exclusive rights to intellectual property related to cysteamine and related compounds in the potential treatment of Parkinson's Disease from Université Laval ("Laval"), Quebec, Canada.

Raptor's agreement with Laval provides exclusive rights to technology related to the use of cysteamine and related compounds to potentially modify the progression of Parkinson's Disease. Researchers at Laval reported that administration of cystamine (an oxidized form of cysteamine) in an animal model of Parkinson's Disease showed signs of preventing neuron loss and rescuing neurons undergoing a degenerative process. Signs of restoration and partial reversal of behavioral impairments were also observed.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Mergers and Acquisitions

Add Your Comment